April 10, 2007 — A new analysis of the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) shows that ibuprofen, relative to the cyclooxygenase (COX)–2 inhibitor lumiracoxib (Prexige; Novartis Pharmaceuticals), increases the risk for thrombotic and congestive heart failure events among high cardiovascular-risk patients with osteoarthritis currently taking aspirin. The results "are consistent with the ability of ibuprofen to interfere with the effects of aspirin on platelet aggregation," said Michael E. Farkouh, MD, from the Mount Sinai School of Medicine in New York, and colleagues. The analysis appears in the April 5 Online First issue of Annals of the Rheumatic Diseases.
"In this group of high-risk patients, when we look specifically at those taking aspirin in the lumiracoxib versus ibuprofen study arm, patients treated with ibuprofen have a significantly higher risk for myocardial infarction, whereas in the lumiracoxib and naproxen comparison there are very similar outcomes with both treatments," Dr. Farkouh told heartwire. "Interestingly, in the group not taking aspirin, lumiracoxib and ibuprofen behaved almost identically. We believe that this is an example, the first time in a randomized trial, that demonstrates that there is a potential interaction between ibuprofen and aspirin and that it does have clinical ramifications."
http://www.medscape.com/viewarticle/554917?rss
No comments:
Post a Comment